Who We Are

King Pharmaceuticals® began operations in January 1994, after purchasing the company’s Bristol Tennessee facility and assuming contracts to manufacture prescription pharmaceutical products for such prominent companies as SmithKline Beecham Corporation, predecessor to GlaxoSmithKline, and Novartis.

For the next ten years, King principally focused on the manufacture, acquisition and marketing of previously approved products. Under new leadership in 2004, the company shifted strategy to become a leading developer and acquirer of novel branded pharmaceutical products in later stages of development. Recently, the Company began accelerating its plan to emphasize its neuroscience, hospital and acute care medicine platforms to capitalize on the its core strengths in and positive dynamics of these marketplaces.

King’s labor force has grown from an initial 145 to over 2000 employees involved in every discipline of a major pharmaceutical company, including sales and marketing, research and development, medical affairs, regulatory affairs, quality management and manufacturing.

Sales and Marketing

As the company has grown, so have its marketing capabilities. Today, King’s dedicated field sales force consists of approximately 690 individuals throughout the U.S. and Puerto Rico, a dramatic increase over the 24 sales professionals employed in 1994.

Research and Development

King’s highly cost-effective, readily scalable R&D model sets it apart from other pharmaceutical companies. Its 70-person strong in-house R&D team includes drug development scientists, regulatory and drug safety staff, who manage the full range of R&D activities for late-stage products: drug discovery, clinical development, drug safety, regulatory affairs, medical affairs and project management.

Manufacturing

King currently operates manufacturing facilities – in Bristol, Tennessee; Rochester, Michigan; St. Louis, Missouri; St. Petersburg, Florida; and Middleton, Wisconsin – that produce a broad array of dosage forms, including tablets, capsules, liquids, suspensions, solutions, suppositories, creams, ointments, injectables, auto-injector products and other drug products.

Financial Highlights

King’s revenues have grown from $13 million in 1994 to over $2.1 billion in 2007. King’s common stock trades on the New York Stock Exchange under the symbol “KG,” and is a component of the S&P 500 Index and the AMEX pharmaceutical index.

Relying on talented and dedicated employees, following a strategic vision and developing trusted relationships with other drug companies, wholesalers, physicians and pharmacists, King is redefining the standards for success in pursuing opportunities in the health care industry. The Company looks forward to continuing its exciting growth and sharing its success with its stakeholders and employees.

About Forward-Looking Statements

The foregoing contains forward-looking statements, which reflect management’s current views of future events and operations, including, but not limited to, statements pertaining to King's future growth. These forward-looking statements involve certain significant risks and uncertainties, and actual results may differ materially from the forward-looking statements. Some important factors, which may cause results to differ include those discussed in the “Risk Factors” section and other sections of King’s Form 10-K for the year ended December 31, 2007, and King’s Form 10-Q for the quarter ended June 30, 2008, which are on file with the Securities and Exchange Commission. To view risk factors pertaining to forward-looking statements, click on the following link: Risk Factors. King does not undertake to publicly update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.

This page was last updated on 11/08/2007.